Aurobindo Pharma Ltd ’s exclusive pact with Covaxx, the US-based company to develop Covid-19 vaccine opens large business scope. This means the company’s growth remains insulated from rising competition in any particular product. Notably, Aurobindo had acquired Natrol in December 2014 at valuations of 2 times enterprise value to sales (EV/sales). Aurobindo is amongst a few Indian pharmaceutical companies to have scaled up European business successfully. The European sales accounting for about fourth of consolidated too had rebounded 14.6% sequentially.

Source: Mint December 25, 2020 14:26 UTC